Wockhardt at all-time high, sees 300% gains in 1 year

Healthcare firm Wockhardt continued its run for the fourth consecutive session to touch a record high of Rs 2,090 on Friday.
 
Shares shot up nearly 12 percent in four days, and more than 300 percent in last one year from the level of Rs 507 seen on March 7, 2012.

Meanwhile, the BSE Healthcare index shot up over 26 percent and Sensex gained 14 percent in last 12 months.

Company's performance in the quarter ending December 2012 was quite strong with the consolidated net profit doubling year-on-year to Rs 427.84 crore. Revenues increased 19 percent YoY to Rs 1,435.04 crore during the quarter.

Events in the last one year:

• On July 26, 2012, it had entered into an agreement with Danone for divestment of its nutrition business for a consideration of Rs 1,280 crore.
• On August 20, the company received US FDA approval for the launch of generic version of Parkinson's drug Comtan with 180-days exclusivity.
• On August 22, US FDA approved generic version of anti-psychotic drug Geodon.
• On August 28, the generic version of Parkinsonism drug Requip XL received US FDA approval.
• On September 3, it launched generic version of anti-depressant drug Wellbutrin SR.
• On September 17, a generic version of anti-ulcer drug Prevacid was rolled out.
• On September 20, the winding-up petition filed by the trustees to the foreign currency convertible bonds before the Hon'ble Bombay high Court was withdrawn.
• On January 8, 2013, company launched generic version of anti-convulsant drug Lamictal XR.

At 12:26 hours IST, shares moved up 1.28 percent to Rs 2,058.90 on Bombay Stock Exchange.